Clinical Updatesclinical trialdexamethasone
Optimizing Therapy in Transplant-Ineligible Multiple Myeloma: Insights from the REST Phase 2 Trial on Isatuximab, Bortezomib, Lenalidomide, and Limited Dexamethasone
By MedXY|Oct 5, 2025
The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.
